DE60234163D1 - Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten - Google Patents

Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten

Info

Publication number
DE60234163D1
DE60234163D1 DE60234163T DE60234163T DE60234163D1 DE 60234163 D1 DE60234163 D1 DE 60234163D1 DE 60234163 T DE60234163 T DE 60234163T DE 60234163 T DE60234163 T DE 60234163T DE 60234163 D1 DE60234163 D1 DE 60234163D1
Authority
DE
Germany
Prior art keywords
rheumatoid arthritis
gene therapy
parts
gene
angiogenic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234163T
Other languages
English (en)
Inventor
Jong-Mook Kim
Seong-Hyun Ho
Eun-Jin Park
Sun-Young Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helixmith Co Ltd
Original Assignee
Viromedica Pacific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromedica Pacific Ltd filed Critical Viromedica Pacific Ltd
Application granted granted Critical
Publication of DE60234163D1 publication Critical patent/DE60234163D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60234163T 2001-01-05 2002-01-03 Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten Expired - Lifetime DE60234163D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010000691 2001-01-05
PCT/KR2002/000001 WO2002053191A1 (en) 2001-01-05 2002-01-03 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof

Publications (1)

Publication Number Publication Date
DE60234163D1 true DE60234163D1 (de) 2009-12-10

Family

ID=36932148

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234163T Expired - Lifetime DE60234163D1 (de) 2001-01-05 2002-01-03 Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten

Country Status (8)

Country Link
US (3) US7175840B2 (de)
EP (1) EP1371377B1 (de)
JP (1) JP2004517117A (de)
KR (1) KR100495316B1 (de)
CN (1) CN1455682A (de)
AT (1) ATE446772T1 (de)
DE (1) DE60234163D1 (de)
WO (1) WO2002053191A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
AU2007219615B2 (en) 2006-03-03 2013-11-28 Promis Neurosciences Inc. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009038771A2 (en) * 2007-09-19 2009-03-26 Massachusetts Institute Of Technology Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
EP2275437A4 (de) 2008-03-18 2011-09-07 Univ Hokkaido Nat Univ Corp Polypeptid und das polypeptid enthaltende pharmazeutische zusammensetzung
EP2431460B1 (de) * 2009-05-13 2015-10-14 Medipost, Co., Ltd. Stammzellendifferenzierung assoziiertes tsp-1, tsp-2 und il-17br
US9040298B2 (en) 2009-05-29 2015-05-26 Medipost Co., Ltd. Method of selecting stem cells having high chondrogenic differentiation capability
AU2014248198B2 (en) * 2013-04-02 2018-11-29 University Of Florida Research Foundation, Inc. Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
JPH064684A (ja) 1992-06-22 1994-01-14 Fujitsu Ltd データ収集装置および方法
WO1994007524A1 (en) 1992-10-02 1994-04-14 California Pacific Medical Center Research Institute Method of treatment of arthritis with platelet factor 4
US5885795A (en) 1994-04-26 1999-03-23 The Children's Medical Center Corporation Methods of expressing angiostatic protein
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
KR100217586B1 (ko) 1995-12-21 1999-09-01 정몽규 자동차의 동적 폐력 측정 장치
AU4401297A (en) 1996-09-21 1998-04-14 Viromedica Pacific Limited Improved retroviral vectors for gene therapy
WO1998051791A1 (fr) * 1997-05-15 1998-11-19 Shunichi Shiozawa Gene responsable de l'arthrite rhumatoide, methode pour diagnostiquer l'arthrite rhumatoide et procede permettant de determiner des facteurs responsables de l'arthrite rhumatoide
JP2002517999A (ja) 1998-06-17 2002-06-25 ベス イスラエル ディーコネス メディカル センター 抗血管形成タンパク質およびその使用方法
KR20000006334A (ko) * 1998-06-26 2000-01-25 이선경 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
JP3726005B2 (ja) 2000-03-09 2005-12-14 株式会社 日立インダストリイズ 多段遠心圧縮機
JP2001256030A (ja) 2000-03-14 2001-09-21 Seiko Epson Corp 印刷システム、印刷制御装置及びプログラム記録媒体
ATE328081T1 (de) 2000-03-29 2006-06-15 Beth Israel Hospital Antiangiogene eigenschaften von vascostatin und fragmenten und varianten davon
EP1197550A3 (de) 2000-08-25 2002-11-20 Pfizer Products Inc. Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
US6803211B2 (en) 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
EP1404359A2 (de) 2000-12-07 2004-04-07 Board Of Regents, The University Of Texas System Behandlungsverfahren mit menschlichem mda-7

Also Published As

Publication number Publication date
US20050277603A1 (en) 2005-12-15
KR100495316B1 (ko) 2005-06-14
US20060198826A1 (en) 2006-09-07
US7175840B2 (en) 2007-02-13
KR20020057824A (ko) 2002-07-12
EP1371377A1 (de) 2003-12-17
ATE446772T1 (de) 2009-11-15
WO2002053191A1 (en) 2002-07-11
JP2004517117A (ja) 2004-06-10
CN1455682A (zh) 2003-11-12
US20060193833A1 (en) 2006-08-31
EP1371377A4 (de) 2006-01-18
EP1371377B1 (de) 2009-10-28

Similar Documents

Publication Publication Date Title
DE60234163D1 (de) Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti-angiogenes protein oder teile davon kodiert, enthalten
FI955420A (fi) BMP-10 koostumukset
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200300845A1 (ru) Модифицированные антитела и способы применения
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE336240T1 (de) Therapeutische verwendung von stickstoffmonoxydinhibitoren
DK0753053T3 (da) Alfavirus-cDNA-vektorer
ES8302778A1 (es) Un procedimiento para producir un polipeptido antiviral.
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DK55086D0 (da) Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
ATE259243T1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
DE69926764D1 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
EA200001124A1 (ru) Способ генной терапии
JPS6420095A (en) Polypeptide having anti-blood coagulating action
DE60335473D1 (de) Primäre kultivierte adipozyten zur gentherapie
BR9708049A (pt) Processo para matar células alvo indesejadas em uma população de células imunotoxinas para matar células uso das mesmas e kit para realizar o processo
ES2147556T3 (es) Proteina relativa al hueso, del tipo carboxipeptidasa y procedimiento para su produccion.
DK1890713T3 (da) Osteoblast-sammensætning af semi-solidificeret blandet fibrin til agglutination af knoglefrakturer og fremgangsmåde til fremstilling deraf
EP1429650A4 (de) Alternativ gesplicter zirkulierender gewebefaktor
EP1497326A4 (de) Prothrombin aktivierendes protein
ES2167322T3 (es) Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: VIROMED CO., LTD., SEOUL/SOUL, KR

8364 No opposition during term of opposition